Acumen Pharmaceuticals Reports Q1 2025 Net Loss of $28.8 Million, Doubling from Previous Year

Reuters
13 May
Acumen Pharmaceuticals Reports Q1 2025 Net Loss of $28.8 Million, Doubling from Previous Year

Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, reported a net loss of $28.8 million for the first quarter of 2025, compared to a net loss of $14.9 million in the same period of 2024. The company holds cash, cash equivalents, and marketable securities totaling $197.9 million as of March 31, 2025, which is expected to support its clinical and operational activities into early 2027. In significant business developments, Acumen has fully enrolled its ALTITUDE-AD Phase 2 study, which investigates the efficacy, safety, and tolerability of sabirnetug for treating early Alzheimer's disease. The study includes 542 participants, and the company anticipates reporting topline results in late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450250-en) on May 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10